Do analysts prefer BBLG or SURG?

SurgePays has a consensus target price of $3.50, indicating a potential upside of 1,058.56%. Given SurgePays' stronger consensus rating and higher probable upside, analysts clearly believe SurgePays is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BBLG or SURG more profitable?

Bone Biologics has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Bone Biologics' return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% SurgePays -64.91% N/A -310.16%

Does the media refer more to BBLG or SURG?

In the previous week, SurgePays had 2 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for SurgePays and 1 mentions for Bone Biologics. SurgePays' average media sentiment score of 0.21 beat Bone Biologics' score of 0.00 indicating that SurgePays is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bone Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SurgePays 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VVOS or BBLG?

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 781.33%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to VVOS or BBLG?

In the previous week, Vivos Therapeutics had 1 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Bone Biologics. Vivos Therapeutics' average media sentiment score of 0.74 beat Bone Biologics' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bone Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NDRA or BBLG?

ENDRA Life Sciences presently has a consensus target price of $25.00, indicating a potential upside of 463.06%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, NDRA or BBLG?

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A Bone Biologics N/A N/A -$3.11M -$2.27 N/A

Is NDRA or BBLG more profitable?

Bone Biologics' return on equity of -50.47% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -433.64% -204.58% Bone Biologics N/A -50.47% -47.40%

Does the media prefer NDRA or BBLG?

In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 1 articles in the media. ENDRA Life Sciences' average media sentiment score of 2.00 beat Bone Biologics' score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ENDRA Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bone Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BBLG or CODX?

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 4,400.00%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BBLG or CODX more profitable?

Bone Biologics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Bone Biologics' return on equity of -50.47% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media refer more to BBLG or CODX?

In the previous week, Bone Biologics and Bone Biologics both had 1 articles in the media. Bone Biologics' average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bone Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BBLG or PAVM?

PAVmed has a consensus price target of $56.00, indicating a potential upside of 1,112.12%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BBLG or PAVM more profitable?

Bone Biologics has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Bone Biologics' return on equity of -50.47% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% PAVmed -21,914.12% -146.19% -18.39%

Does the media favor BBLG or PAVM?

In the previous week, PAVmed had 2 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for PAVmed and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bone Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bone Biologics (BBLG) Competitors

$0.88 -0.05 (-5.67%)

As of 03:59 PM Eastern

Compare

BBLG vs. SURG, VVOS, NDRA, CODX, and PAVM

Should you buy Bone Biologics stock or one of its competitors? Bone Biologics's main competitors and comparable companies include SurgePays (SURG), Vivos Therapeutics (VVOS), ENDRA Life Sciences (NDRA), Co-Diagnostics (CODX), and PAVmed (PAVM). Companies are selected based on similarities in market, industry, and size.

How does Bone Biologics compare to SurgePays?

Bone Biologics (NASDAQ:BBLG) and SurgePays (NASDAQ:SURG) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Bone Biologics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, SurgePays has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 5.6% of Bone Biologics shares are held by insiders. Comparatively, 29.1% of SurgePays shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, SurgePays had 2 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for SurgePays and 1 mentions for Bone Biologics. SurgePays' average media sentiment score of 0.21 beat Bone Biologics' score of 0.00 indicating that SurgePays is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bone Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SurgePays	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bone Biologics has higher earnings, but lower revenue than SurgePays. Bone Biologics is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
SurgePays	$56.96M	0.13	-$36.07M	-$1.94	N/A

SurgePays has a consensus target price of $3.50, indicating a potential upside of 1,058.56%. Given SurgePays' stronger consensus rating and higher probable upside, analysts clearly believe SurgePays is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Bone Biologics has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Bone Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
SurgePays	-64.91%	N/A	-310.16%

Summary

SurgePays beats Bone Biologics on 9 of the 14 factors compared between the two stocks.

How does Bone Biologics compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Bone Biologics has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Bone Biologics' return on equity of -50.47% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Bone Biologics	N/A	-50.47%	-47.40%

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 5.6% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bone Biologics has lower revenue, but higher earnings than Vivos Therapeutics. Bone Biologics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.25	-$21.17M	-$2.14	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

In the previous week, Vivos Therapeutics had 1 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Bone Biologics. Vivos Therapeutics' average media sentiment score of 0.74 beat Bone Biologics' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bone Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 781.33%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vivos Therapeutics has a beta of 6.22, meaning that its stock price is 522% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Summary

Vivos Therapeutics beats Bone Biologics on 8 of the 14 factors compared between the two stocks.

How does Bone Biologics compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 1 articles in the media. ENDRA Life Sciences' average media sentiment score of 2.00 beat Bone Biologics' score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ENDRA Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bone Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bone Biologics' return on equity of -50.47% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Bone Biologics	N/A	-50.47%	-47.40%

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 5.6% of Bone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ENDRA Life Sciences presently has a consensus target price of $25.00, indicating a potential upside of 463.06%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Summary

Bone Biologics beats ENDRA Life Sciences on 6 of the 11 factors compared between the two stocks.

How does Bone Biologics compare to Co-Diagnostics?

Bone Biologics (NASDAQ:BBLG) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Bone Biologics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.88, indicating that its share price is 188% more volatile than the broader market.

Bone Biologics has higher earnings, but lower revenue than Co-Diagnostics. Bone Biologics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
Co-Diagnostics	$620K	8.93	-$46.90M	-$15.77	N/A

In the previous week, Bone Biologics and Bone Biologics both had 1 articles in the media. Bone Biologics' average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bone Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 4,400.00%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 5.6% of Bone Biologics shares are owned by company insiders. Comparatively, 2.3% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bone Biologics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Bone Biologics' return on equity of -50.47% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

Summary

Bone Biologics beats Co-Diagnostics on 7 of the 12 factors compared between the two stocks.

How does Bone Biologics compare to PAVmed?

Bone Biologics (NASDAQ:BBLG) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Bone Biologics has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Bone Biologics' return on equity of -50.47% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
PAVmed	-21,914.12%	-146.19%	-18.39%

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 5.6% of Bone Biologics shares are owned by company insiders. Comparatively, 13.4% of PAVmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PAVmed has higher revenue and earnings than Bone Biologics. Bone Biologics is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
PAVmed	$70K	66.00	$400K	-$37.40	N/A

In the previous week, PAVmed had 2 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for PAVmed and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bone Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PAVmed has a consensus price target of $56.00, indicating a potential upside of 1,112.12%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bone Biologics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Summary

PAVmed beats Bone Biologics on 8 of the 13 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBLG vs. The Competition

Export

Metric	Bone Biologics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.69M	$5.79B	$7.06B	$12.95B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	N/A	24.71	269.75	24.74
Price / Sales	N/A	67.44	652.34	108.60
Price / Cash	N/A	33.55	28.89	37.44
Price / Book	0.29	6.21	11.27	6.42
Net Income	-$3.11M	$147.87M	$3.45B	$347.12M
7 Day Performance	-2.27%	3.40%	3.56%	2.48%
1 Month Performance	-36.72%	1.66%	-0.58%	-1.04%
1 Year Performance	-62.25%	6.26%	77.52%	23.22%

Bone Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBLG Bone Biologics	0.8835 of 5 stars	$0.88 -5.7%	N/A	-60.0%	$1.69M	N/A	N/A	2	Upcoming Earnings
SURG SurgePays	3.1261 of 5 stars	$0.22 -8.1%	$3.50 +1,520.4%	-90.1%	$5.90M	$56.96M	N/A	40	Upcoming Earnings Gap Down
VVOS Vivos Therapeutics	2.0394 of 5 stars	$0.41 -1.9%	$2.80 +589.8%	-92.6%	$5.75M	$17.44M	N/A	160	Positive News
NDRA ENDRA Life Sciences	3.1683 of 5 stars	$4.33 -2.7%	$25.00 +477.4%	+5.3%	$5.65M	N/A	N/A	20	Positive News Upcoming Earnings Gap Up
CODX Co-Diagnostics	1.5124 of 5 stars	$1.56 +3.3%	$67.50 +4,226.9%	-80.1%	$5.56M	$620K	N/A	100	Upcoming Earnings High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBLG) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bone Biologics (BBLG) Competitors

BBLG vs. SURG, VVOS, NDRA, CODX, and PAVM

How does Bone Biologics compare to SurgePays?

Summary

How does Bone Biologics compare to Vivos Therapeutics?

Summary

How does Bone Biologics compare to ENDRA Life Sciences?

Summary

How does Bone Biologics compare to Co-Diagnostics?

Summary

How does Bone Biologics compare to PAVmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bone Biologics (BBLG) Competitors

BBLG vs. SURG, VVOS, NDRA, CODX, and PAVM

How does Bone Biologics compare to SurgePays?

Which has more risk and volatility, BBLG or SURG?

Do insiders and institutionals believe in BBLG or SURG?

Does the media refer more to BBLG or SURG?

Which has stronger earnings & valuation, BBLG or SURG?

Do analysts prefer BBLG or SURG?

Is BBLG or SURG more profitable?

Summary

How does Bone Biologics compare to Vivos Therapeutics?

Is VVOS or BBLG more profitable?

Do institutionals & insiders believe in VVOS or BBLG?

Which has higher valuation & earnings, VVOS or BBLG?

Does the media refer more to VVOS or BBLG?

Do analysts rate VVOS or BBLG?

Which has more risk & volatility, VVOS or BBLG?

Summary

How does Bone Biologics compare to ENDRA Life Sciences?

Does the media prefer NDRA or BBLG?

Is NDRA or BBLG more profitable?

Which has preferable valuation & earnings, NDRA or BBLG?

Do institutionals and insiders have more ownership in NDRA or BBLG?

Do analysts recommend NDRA or BBLG?

Which has more volatility and risk, NDRA or BBLG?

Summary

How does Bone Biologics compare to Co-Diagnostics?

Which has more volatility & risk, BBLG or CODX?

Which has preferable valuation & earnings, BBLG or CODX?

Does the media refer more to BBLG or CODX?

Do analysts recommend BBLG or CODX?

Do institutionals & insiders believe in BBLG or CODX?

Is BBLG or CODX more profitable?

Summary

How does Bone Biologics compare to PAVmed?

Is BBLG or PAVM more profitable?

Do institutionals & insiders believe in BBLG or PAVM?

Which has higher valuation and earnings, BBLG or PAVM?

Does the media favor BBLG or PAVM?

Do analysts rate BBLG or PAVM?

Which has more volatility and risk, BBLG or PAVM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools